Galectin Therapeutics (GALT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Dec, 2025Opening remarks and agenda
The meeting was called to order by the Vice Chairman, with introductions of the Board, management, and key advisors present, and an agenda was provided via the virtual meeting platform.
The meeting was held virtually for cost savings and efficiency, with technical support available for participants.
Board and executive committee updates
The full Board of Directors and executive management were introduced, including committee memberships and roles.
The Inspector of Elections and legal and accounting advisors were also present.
Shareholder proposals
Four proposals were presented: election of 11 directors, advisory vote on executive compensation, vote on frequency of compensation votes, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Galectin Therapeutics
- Belapectin reduced new varices in MASH cirrhosis and showed promise in cancer therapy.GALT
Corporate presentation16 Mar 2026 - Belapectin reduced new varices and improved fibrosis biomarkers in advanced MASH cirrhosis.GALT
KOL event10 Mar 2026 - Belapectin shows promise in late-stage NASH cirrhosis trials, targeting a major unmet need.GALT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - NAVIGATE trial interim data in Q4 may establish belapectin as a first-in-class cirrhosis therapy.GALT
9th Annual MASH Investor Conference19 Jan 2026 - Virtual 2025 meeting covers director elections, executive pay, auditor ratification, and governance.GALT
Proxy Filing2 Dec 2025 - Virtual annual meeting to elect directors, ratify auditors, and address governance and compensation.GALT
Proxy Filing2 Dec 2025 - Virtual annual meeting to elect directors and ratify auditor, with board support for all proposals.GALT
Proxy Filing2 Dec 2025 - Key votes include director elections, executive pay, and auditor ratification at the 2025 meeting.GALT
Proxy Filing2 Dec 2025 - Net loss narrowed as R&D costs fell; belapectin showed antifibrotic activity in MASH cirrhosis.GALT
Q3 202514 Nov 2025